Minggui Pan1,2, James S Chang1. 1. Department of Oncology and Hematology, Kaiser Permanente, Santa Clara, CA. 2. Division of Research, Kaiser Permanente, Santa Clara, CA.
Abstract
INTRODUCTION: NUT carcinoma is an extremely rare disease and yet extremely aggressive with 2-year survival of only approximately 19% and median survival of 6 to 9 months. CASE PRESENTATION: We report here 2 successfully treated patients with durable complete remission (CR) after concurrent chemotherapy and radiation using 2 completely different chemotherapy regimens. One patient had extremely high tumor burden and obtained CR with ifosfamide and etoposide concurrently with radiation. One patient with low tumor burden obtained CR with carboplatin and paclitaxel concurrently with radiation. Interestingly, both patients had high PD-L1 expression in the tumor that may be associated with the favorable outcome. CONCLUSION: Our experiences with these 2 successfully treated patients offer insight for the management of NUT carcinoma.
INTRODUCTION: NUT carcinoma is an extremely rare disease and yet extremely aggressive with 2-year survival of only approximately 19% and median survival of 6 to 9 months. CASE PRESENTATION: We report here 2 successfully treated patients with durable complete remission (CR) after concurrent chemotherapy and radiation using 2 completely different chemotherapy regimens. One patient had extremely high tumor burden and obtained CR with ifosfamide and etoposide concurrently with radiation. One patient with low tumor burden obtained CR with carboplatin and paclitaxel concurrently with radiation. Interestingly, both patients had high PD-L1 expression in the tumor that may be associated with the favorable outcome. CONCLUSION: Our experiences with these 2 successfully treated patients offer insight for the management of NUT carcinoma.
Authors: Daniel E Bauer; Chelsey M Mitchell; Kelly M Strait; Christopher S Lathan; Edward B Stelow; Sonja C Lüer; Somala Muhammed; Andrew G Evans; Lynette M Sholl; Juan Rosai; Eugenia Giraldi; Richard P Oakley; Carlos Rodriguez-Galindo; Wendy B London; Stephen E Sallan; James E Bradner; Christopher A French Journal: Clin Cancer Res Date: 2012-08-15 Impact factor: 12.531
Authors: Nicole G Chau; Shelley Hurwitz; Chelsey M Mitchell; Alexandra Aserlind; Noam Grunfeld; Leah Kaplan; Peter Hsi; Daniel E Bauer; Christopher S Lathan; Carlos Rodriguez-Galindo; Roy B Tishler; Robert I Haddad; Stephen E Sallan; James E Bradner; Christopher A French Journal: Cancer Date: 2016-08-10 Impact factor: 6.860
Authors: Adlai R Grayson; Erica M Walsh; Michael J Cameron; Jernej Godec; Todd Ashworth; Jessica M Ambrose; Alexandra B Aserlind; Hongfang Wang; Gerard Evan; Michael J Kluk; James E Bradner; Jon C Aster; Christopher A French Journal: Oncogene Date: 2013-04-22 Impact factor: 9.867